|
Eine Ebene nach oben |
Gruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 6
Zeitschriftenartikel
Scheubeck, Gabriel 
ORCID: https://orcid.org/0009-0004-2546-6154; Hoffmann, Martin; Jurinovic, Vindi; Fischer, Luca ORCID: https://orcid.org/0000-0003-2444-416X; Unterhalt, Michael; Schmidt, Christian; Böck, Hans-Peter; Dührsen, Ulrich; Kaesberger, Joachim; Kremers, Stephan; Lindemann, Hans-Walter; Mantovani, Luisa; Hiddemann, Wolfgang; Hoster, Eva ORCID: https://orcid.org/0000-0002-0749-1389 und Dreyling, Martin ORCID: https://orcid.org/0000-0002-0358-5249
(2024):
Rituximab, gemcitabine and oxaliplatin in relapsed or refractory indolent and mantle cell lymphoma: results of a multicenter phase I/II-study of the German Low Grade Lymphoma Study Group.
In: Annals of Hematology [Forthcoming]
ORCID: https://orcid.org/0009-0004-2546-6154; Hoffmann, Martin; Jurinovic, Vindi; Fischer, Luca ORCID: https://orcid.org/0000-0003-2444-416X; Unterhalt, Michael; Schmidt, Christian; Böck, Hans-Peter; Dührsen, Ulrich; Kaesberger, Joachim; Kremers, Stephan; Lindemann, Hans-Walter; Mantovani, Luisa; Hiddemann, Wolfgang; Hoster, Eva ORCID: https://orcid.org/0000-0002-0749-1389 und Dreyling, Martin ORCID: https://orcid.org/0000-0002-0358-5249
(2024):
Rituximab, gemcitabine and oxaliplatin in relapsed or refractory indolent and mantle cell lymphoma: results of a multicenter phase I/II-study of the German Low Grade Lymphoma Study Group.
In: Annals of Hematology [Forthcoming]
Fischer, Luca ORCID: https://orcid.org/0000-0003-2444-416X; Jiang, Linmiao ORCID: https://orcid.org/0000-0002-9009-4236; Bittenbring, Joerg Thomas; Huebel, Kai; Schmidt, Christian; Duell, Johannes; Metzner, Bernd; Krauter, Juergen; Glass, Bertram; Huettmann, Andreas; Schaefer-Eckart, Kerstin; Silkenstedt, Elisabeth; Klapper, Wolfram; Hiddemann, Wolfgang; Unterhalt, Michael; Dreyling, Martin und Hoster, Eva ORCID: https://orcid.org/0000-0002-0749-1389
(2023):
The addition of rituximab to chemotherapy improves overall survival in mantle cell lymphoma—a pooled trials analysis.
In: Annals of Hematology, Bd. 102: S. 2791-2801
[PDF, 1MB]
ORCID: https://orcid.org/0000-0003-2444-416X; Jiang, Linmiao ORCID: https://orcid.org/0000-0002-9009-4236; Bittenbring, Joerg Thomas; Huebel, Kai; Schmidt, Christian; Duell, Johannes; Metzner, Bernd; Krauter, Juergen; Glass, Bertram; Huettmann, Andreas; Schaefer-Eckart, Kerstin; Silkenstedt, Elisabeth; Klapper, Wolfram; Hiddemann, Wolfgang; Unterhalt, Michael; Dreyling, Martin und Hoster, Eva ORCID: https://orcid.org/0000-0002-0749-1389
(2023):
The addition of rituximab to chemotherapy improves overall survival in mantle cell lymphoma—a pooled trials analysis.
In: Annals of Hematology, Bd. 102: S. 2791-2801
[PDF, 1MB]
Moosburner, Marie; Alibegovic, Lamija; Hasselmann, Korbinian ORCID: https://orcid.org/0009-0000-5907-6841; Gaiderov, Anton; Hildebrand, Johannes; Philippou‐Massier, Julia; Blum, Helmut; Fischer, Luca ORCID: https://orcid.org/0000-0003-2444-416X; Dreyling, Martin ORCID: https://orcid.org/0000-0002-0358-5249 und Silkenstedt, Elisabeth ORCID: https://orcid.org/0000-0003-2676-0860
(2023):
Combined treatment with crizotinib and temsirolimus is an effective strategy in mantle cell lymphoma and can overcome acquired resistance to temsirolimus.
In: Hematological Oncology, Bd. 41, Nr. 5: S. 858-868
[PDF, 1MB]
ORCID: https://orcid.org/0009-0000-5907-6841; Gaiderov, Anton; Hildebrand, Johannes; Philippou‐Massier, Julia; Blum, Helmut; Fischer, Luca ORCID: https://orcid.org/0000-0003-2444-416X; Dreyling, Martin ORCID: https://orcid.org/0000-0002-0358-5249 und Silkenstedt, Elisabeth ORCID: https://orcid.org/0000-0003-2676-0860
(2023):
Combined treatment with crizotinib and temsirolimus is an effective strategy in mantle cell lymphoma and can overcome acquired resistance to temsirolimus.
In: Hematological Oncology, Bd. 41, Nr. 5: S. 858-868
[PDF, 1MB]
Salles, Gilles; Schuster, Stephen J.; Fischer, Luca; Kuruvilla, John; Patten, Piers Em; Tresckow, Bastian von; Smith, Sonali M.; Ubieto, Ana Isabel Jiminez; Davis, Keith L.; Nagar, Saurabh P.; Zhang, Jie; Bollu, Vamsi; Jousseaume, Etienne; Ramos, Roberto; Wang, Yucai und Link, Brian K.
(2022):
A Retrospective Cohort Study of Treatment Outcomes of Adult Patients With Relapsed or Refractory Follicular Lymphoma (ReCORD-FL).
In: Hemasphere, Bd. 6, Nr. 7, e745
Salles, Gilles; Schuster, Stephen J.; Dreyling, Martin; Fischer, Luca; Kuruvilla, John; Patten, Piers E. M.; Tresckow, Bastian von; Smith, Sonali M.; Jimenez-Ubieto, Ana; Davis, Keith L.; Anjos, Carla; Chu, Jufen; Zhang, Jie; Bodoni, Chiara Lobetti; Thieblemont, Catherine; Fowler, Nathan H.; Dickinson, Michael; Martinez-Lopez, Joaquin; Wang, Yucai und Link, Brian K.
(2022):
Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma.
In: Blood Advances, Bd. 6, Nr. 22: S. 5835-5843
Mümmler, Carlo; Zhang, Danmei; Zimmermann, Andreas; Mertsch, Pontus; Fischer, Luca; Greither, Margarete; Khatamzas, Elham; Ormanns, Steffen; Heiß-Neumann, Marion; Dreyling, Martin; Bergwelt-Baildon, Michael von und Boeck, Stefan
(2021):
Rituximab Treatment of Hairy Cell Leukemia in a Patient with Mycobacterium kansasii Infection: A Case Report.
In: Oncology Research and Treatment, Bd. 44, Nr. 11: S. 637-640